Table 2 Clinical characteristics of axSpA participants
axSpA (71) | axSpa 1 year retention (60) | axSpa 1 year suspension (11) | p | axSpa 2 year retention (57) | axSpa 2 year suspension (14) | p | |
|---|---|---|---|---|---|---|---|
Age | 49 (37–58) | 51 (38–60) | 44 (35–46) | 0.10 | 49 (37–58) | 46 (43–56) | 0.78 |
Female (%) | 43.66 | 40.32 | 66.67 | 0.13 | 37.93 | 69.23 | 0.040 |
Disease duration (months) | 72 (48–120) | 87 (50–132) | 48 (18–60) | 0.0083 | 87 (50–132) | 59 (21–75) | 0.035 |
BMI | 26.04 (23.5–30.4) | 26.22 (23.63–30.45) | 24.7 (22.6–30.1) | 0.61 | 26.4 (23.9–30.5) | 24.14 (20.35–29.6) | 0.20 |
Fibromyalgia (%) | 12.5 | 12.73 | 11.11 | 0.89 | 13.46 | 8.33 | 0.63 |
Smokers (%) yes | 28.17 | 25.81 | 44.44 | 0.36 | 25.86 | 38.46 | 0.34 |
ex | 9.86 | 11.29 | 0.00 | 12.07 | 0.00 | ||
Peripheral arthritis (%) | 54.53 | 0 | 100 | < 0.0001 | 0 | 100 | < 0.0001 |
HLA B27 (%) | 43.08 | 45.61 | 25 | 0.27 | 47.17 | 25.00 | 0.16 |
Positive MRI (%) | 74.65 | 74.19 | 77.78 | 0.82 | 75.86 | 69.23 | 0.62 |
Positive Rx (%) | 49.28 | 50 | 44.44 | 0.76 | 50 | 46.15 | 0.80 |
Active Uveitis (%) | 1.41 | 1.61 | 0 | 0.91 | 1.72 | 0 | 0.80 |
Past uveitis (%) | 19.72 | 19.35 | 22.22 | 0.91 | 20.69 | 15.38 | 0.80 |
csDMARDs use (%) | 22.12 | 12.96 | 11.76 | 0.90 | 25.86 | 15.38 | 0.42 |
bDMARDs use (%) | 91.23 | 42.86 | 9.38 | 0.011 | 93.10 | 76.92 | 0.08 |
Ccs (%) | 5.63 | 6.45 | 0 | 0.43 | 6.9 | 0 | 0.33 |
NSAIDs (%) | 47.89 | 45.16 | 66.67 | 0.23 | 44.83 | 61.54 | 0.28 |
SNRI (%) | 2.82 | 1.61 | 11.11 | 0.11 | 0 | 15.38 | 0.002 |
Tricyclic antidepressant (%) | 4.23 | 4.84 | 0 | 0.5 | 3.45 | 7.69 | 0.49 |
Anticonvulsivant drugs use (%) | 8.45 | 8.06 | 11.11 | 0.76 | 6.9 | 15.38 | 0.32 |
Myorelaxant agent (%) | 9.86 | 8.06 | 22.22 | 0.18 | 8.62 | 15.38 | 0.46 |
Opioid drugs (%) | 4.23 | 3.23 | 11.11 | 0.27 | 3.45 | 7.69 | 0.49 |
LEI | 0 (0–0) | 0 (0–0) | 0 (0–1.5) | 0 (0–0) | 0 (0–1.5) | ||
CRP | 0.2 (0.08–0.5) | 0.14 (0.07–0.44) | 0.55 (0.42–2.23) | 0.0213 | 0.13 (0.07–0.43) | 0.5 (0.32–1.4) | 0.017 |
ESR | 9 (4–19) | 8 (4–19) | 12(9–14) | 0.20 | 8 (4–18) | 14 (9–25) | 0.07 |
BASDAI | 4.17 (2.1–6.3) | 3.88 (2–5.8) | 7 (6–9) | 0.0023 | 3.75 (2–5.7) | 7 (6–8.8) | 0.0002 |
PtGA | 5 (3–8) | 4.5 (2.5–7) | 8 (7–10) | 0.0081 | 4 (2–75) | 8 (7–10) | 0.0014 |
PhyGA | 1 (0–3) | 1(0–3) | 3 (1–6.5) | 0.23 | 1 (0–3) | 1 (25–6.5) | 0.14 |
ASDAS-PCR | 2.32 (1.29–3.16) | 2.25 (1.25–2.99) | 3.37 (2.48–4.12) | 0.0192 | 2.19 (1.24—2.84) | 3.35 (2.45–3.91) | 0.0042 |
BASFI | 5.7 (0.3–16) | 4.9 (0.3–16) | 7.9 (6.8–9.5) | 0.18 | 4.9 (0.3–16) | 6.8 (4.6–9.5) | 0.32 |
PCS | 16 (6–28) | 13.5 (6–25.5) | 40 (30–44) | 0.0002 | 12.5 (6–25.5) | 31 (25–44) | 0.0001 |
Helplessness | 7 (2–12) | 5 (2–10) | 18.5 (13.5–21) | 0.0002 | 5 (2–10) | 16 (11–20) | 0.0004 |
Rumination | 7 (4–12) | 6(3–11) | 16 (9.5–18.5) | 0.0018 | 6 (2–11) | 13 (7–18) | 0.0018 |
Magnification | 2 (0–4) | 2 (0–3) | 5.5 (2.5–6.5) | 0.007 | 2 (0–3) | 4 (2–6) | 0.0712 |
HADS anxiety | 7 (4–10) | 6 (3–10) | 9 (8–11) | 0.023 | 7 (3–10) | 9 (5–11) | 0.14 |
HADS depression | 5 (2–6) | 4 (1–6) | 6 (5–10) | 0.044 | 4 (2–6) | 5 (3–9) | 0.27 |
Acceptance and Action Questionnaire II (AAQ) | 14 (9–22) | 13 (9–22) | 17(15–21) | 0.22 | 13 (9–22) | 17 (13–21) | 0.41 |
Trait Hope Scale (THS) | 24 (22–28) | 25 (22–28) | 22 (19–24) | 0.0371 | 25 (22–28) | 22 (20–25) | 0.14 |
THS agency | 12 (10–14) | 12 (11–14) | 10 (9–13) | 0.1 | 12 (11–14) | 11 (10–13) | 0.33 |
THS pathway | 12 (11–14) | 12 (11–15) | 11 (10–12) | 0.0192 | 12 (11–15) | 12 (10–12) | 0.081 |
Compassionate Engagement and Action Scales – self compassion | 74.5 (64–88) | 75 (67–90) | 68 (63–75) | 0.17 | 75 (67–90) | 68 (63–75) | 0.09 |
Compassionate Engagement and Action Scales- compassion from others | 66 (52–83) | 68.5 (55–83) | 61 (52–69) | 0.32 | 69 (55–83) | 62 (52–69) | 0.22 |